Skip to main content

Ajovy News

FDA Approves Expanded Indication for Ajovy (fremanezumab-vfrm), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine

PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) – Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the...

Teva Announces FDA Approval of Ajovy (fremanezumab-vfrm) Injection Autoinjector

PARSIPPANY, N.J.--(BUSINESS WIRE) January 28, 2020 – Teva Pharmaceuticals USA, Inc. an affiliate ofTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the Food and Drug...

FDA Approves Ajovy (fremanezumab-vfrm) for Preventive Treatment of Migraine

September 14, 2018 – Today, the US Food and Drug Administration (FDA) approved Ajovy (fremanezumab-vfrm) for the preventive treatment of migraine in adults. Ajovy is the second FDA-approved...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Migraine Prevention, Migraine Prophylaxis

Ajovy patient information at Drugs.com